Vaccine delivery is a critical aspect of immunization programs, focusing on methods to administer vaccines effectively and safely to target populations. Traditional vaccine delivery methods include intramuscular or subcutaneous injections, widely used for routine immunizations. More recently, advances in needle-free technologies, such as jet injectors and microneedle patches, aim to improve vaccine accessibility and reduce pain associated with injections. Oral vaccines, administered through the mouth, offer a convenient and non-invasive alternative, particularly advantageous for mass vaccination campaigns. Intranasal delivery, using nasal sprays or droplets, targets the mucosal immune system, providing protection at the site of pathogen entry. Cold chain management is crucial for preserving vaccine efficacy during transportation and storage. Innovations like heat-stable vaccines and controlled-release formulations aim to mitigate challenges associated with cold chain requirements, especially in resource-limited settings. The COVID-19 pandemic has witnessed the rapid deployment of novel vaccine delivery approaches, including mRNA vaccines delivered through intramuscular injections and viral vector vaccines. These developments underscore the dynamic nature of vaccine delivery strategies, emphasizing accessibility, ease of administration, and adaptability to diverse healthcare settings. Ongoing research explores innovative delivery technologies to enhance vaccine coverage and address global health challenges.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey